selected publications
-
academic article
-
Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with type 2-diabetes and microalbuminuria.
Journal of Diabetes and its Complications.
32.
2018
Baseline characteristics and enrichment results from the SONAR trial.
Diabetes Obesity and Metabolism.
20.
2018
Biomarkers of inflammation and endothelial dysfunction as predictors of pulse pressure and incident hypertension in type 1 diabetes: a 20 year life-course study in an inception cohort.
Diabetologia.
61.
2018
Determining the optimal dose of atrasentan by evaluating the exposure‐response relationships of albuminuria and bodyweight.
Diabetes Obesity and Metabolism.
20.
2018
Effect of Insulin Analogs on Frequency of Non–Severe Hypoglycemia in Patients with Type 1 Diabetes Prone to Severe Hypoglycemia: Much Higher Rates Detected by Continuous Glucose Monitoring than by Self-Monitoring of Blood Glucose—The HypoAna Trial.
Diabetes Technology & Therapeutics.
20.
2018
Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes – An observational follow-up study.
PLoS ONE.
13.
2018
Higher Collagen VI Formation Is Associated With All-Cause Mortality in Patients With Type 2 Diabetes and Microalbuminuria.
Diabetes Care.
41.
2018
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.
Diabetes Obesity and Metabolism.
20.
2018
Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study.
Diabetologia.
61.
2018
SP418COLLAGEN TYPE III DEGRADATION IS ASSOCIATED WITH DETERIORATION OF KIDNEY FUNCTION IN PATIENTS WITH TYPE 2 DIABETES WITH MICROALBUMINURIA..
Nephrology,Dialysis and Transplantation.
33.
2018
Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial.
Diabetologia.
61.
2018
Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria.
Cardiovascular Diabetology.
17.
2018
Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients.
Acta Diabetologica.
55.
2018
Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies.
Cardiovascular Diabetology.
16.
2017
Comparing effects of insulin analogues and human insulin on nocturnal glycaemia in hypoglycaemia‐prone people with Type 1 diabetes.
Diabetic Medicine.
34.
2017
Comparison of exposure response relationship of atrasentan between North American and Asian populations.
Diabetes Obesity and Metabolism.
19.
2017
ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD.
American Journal of Kidney Diseases.
70.
2017
Epicardial, pericardial and total cardiac fat and cardiovascular disease in type 2 diabetic patients with elevated urinary albumin excretion rate.
European Journal of Preventive Cardiology.
24.
2017
Higher Plasma Methylglyoxal Levels are Associated with Incident Cardiovascular Disease in Individuals with Type 1 Diabetes: a 12-Year Follow-Up Study.
Diabetes.
66.
2017
Incident microalbuminuria and complement factor mannan‐binding lectin‐associated protein 19 in people with newly diagnosed type 1 diabetes.
Diabetes/Metabolism Research and Reviews.
33.
2017
Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits.
Kidney International.
91.
2017
Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial.
Drugs in R&D.
17.
2017
Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy.
Kidney International.
92.
2017
Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study.
Cardiovascular Diabetology.
16.
2017
Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria.
Cardiovascular Diabetology.
16.
2017
The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy.
Diabetes Obesity and Metabolism.
19.
2017
The potential for improvement of outcomes by personalized insulin treatment of type 1 diabetes as assessed by analysis of single-patient data from a randomized controlled cross-over insulin trial.
Diabetes Research and Clinical Practice.
123.
2017
Toe–brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuria.
Diabetologia.
60.
2017
Are human endogenous retroviruses triggers of autoimmune diseases? Unveiling associations of three diseases and viral loci.
Immunologic Research.
64.
2016
Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney Disease.
Journal of the American Society of Nephrology.
27.
2016
Early renin‐angiotensin system intervention is more beneficial than late intervention in delaying end‐stage renal disease in patients with type 2 diabetes.
Diabetes Obesity and Metabolism.
18.
2016
Effect of insulin analogues on frequency of non-severe hypoglycaemia in patients with type 1 diabetes prone to severe hypoglycaemia: The HypoAna trial.
Diabetes & Metabolism.
42.
2016
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes..
New England Journal of Medicine.
375.
2016
High osteoprotegerin is associated with development of foot ulcer in type 1 diabetes.
Journal of Diabetes and its Complications.
30.
2016
Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial.
Diabetes Obesity and Metabolism.
18.
2016
Markers of inflammation and endothelial dysfunction are associated with incident cardiovascular disease, all-cause mortality, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria.
Journal of Diabetes and its Complications.
30.
2016
Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers.
European Journal of Preventive Cardiology.
23.
2016
Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review.
Journal of the Renin-Angiotensin-Aldosterone System.
17.
2016
Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia—the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT).
Journal of Human Hypertension.
30.
2016
Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.
The Lancet Diabetes & Endocrinology.
4.
2016
Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes.
Journal of Diabetes and its Complications.
30.
2016
Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus.
Journal of Translational Medicine.
14.
2016
Urinary biomarkers are associated with incident cardiovascular disease, all-cause mortality and deterioration of kidney function in type 2 diabetic patients with microalbuminuria.
Diabetologia.
59.
2016
Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study..
Nephrology,Dialysis and Transplantation.
32.
2016
Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial.
Diabetologia.
59.
2016
ACTH stimulation test in patients with type 1 diabetes and recurrent severe hypoglycaemia.
Clinical Endocrinology.
82.
2015
Additive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcification for cardiovascular events and mortality in asymptomatic patients with type 2 diabetes.
Cardiovascular Diabetology.
14.
2015
Effects of RAS inhibitors on diabetic retinopathy.
The Lancet Diabetes & Endocrinology.
3.
2015
IGFBP-4 Fragments as Markers of Cardiovascular Mortality in Type 1 Diabetes Patients With and Without Nephropathy.
The Journal of Clinical Endocrinology & Metabolism.
100.
2015
Improved cardiorenal prognosis in diabetic nephropathy.
Nature Reviews Nephrology.
11.
2015
Improved prognosis of diabetic nephropathy in type 1 diabetes.
Kidney International.
87.
2015
Increased All-Cause Mortality in Patients With Type 1 Diabetes and High-Expression Mannan-Binding Lectin Genotypes: A 12-Year Follow-up Study.
Diabetes Care.
38.
2015
Microalbuminuria: A parameter that has changed diabetes care.
Diabetes Research and Clinical Practice.
107.
2015
Number and Frequency of Albuminuria Measurements in Clinical Trials in Diabetic Nephropathy.
Clinical Journal of the American Society of Nephrology.
10.
2015
Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial.
The Lancet Diabetes & Endocrinology.
3.
2015
SORBS1 gene, a new candidate for diabetic nephropathy: results from a multi-stage genome-wide association study in patients with type 1 diabetes.
Diabetologia.
58.
2015
The renal protective effect of angiotensin receptor blockers depends on intra‐individual response variation in multiple risk markers.
British Journal of Clinical Pharmacology.
80.
2015
A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers.
European Journal of Preventive Cardiology.
21.
2014
Association of the pattern recognition molecule H-ficolin with incident microalbuminuria in an inception cohort of newly diagnosed type 1 diabetic patients: an 18 year follow-up study.
Diabetologia.
57.
2014
Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial.
The Lancet Diabetes & Endocrinology.
2.
2014
Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Non–Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT).
American Journal of Kidney Diseases.
63.
2014
Improved Survival and Renal Prognosis of Patients With Type 2 Diabetes and Nephropathy With Improved Control of Risk Factors.
Diabetes Care.
37.
2014
The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy.
Journal of the American Society of Nephrology.
25.
2014
Visit-to-Visit Variability in Blood Pressure and Kidney and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Nephropathy: A Post Hoc Analysis From the RENAAL Study and the Irbesartan Diabetic Nephropathy Trial.
American Journal of Kidney Diseases.
64.
2014
-
dataset
-
Clinical characteristics of the study population at baseline categorized according to growth differentiation factor 15 and fibroblast growth factor 23 below or above the median..
public-library-of-science.
2018
Stepwise Cox regression analyses: Biomarkers in relation to risk of fatal and nonfatal cardiovascular events, all-cause mortality and decline in eGFR >30% in 200 patients..
public-library-of-science.
2018
-
hide from search
-
Characteristics of samples successfully analyzed in each discovery collection and the meta-analyses..
public-library-of-science.
2012
New Susceptibility Loci Associated with Kidney Disease in Type 1 Diabetes.
public-library-of-science.
2012
Results from discovery, second stage, and combined meta-analysis for supported markers..
public-library-of-science.
2012
Characteristics of the families genotyped for the linkage study..
public-library-of-science.
2011
Clinical characteristics of examined diabetic siblings according to renal status..
public-library-of-science.
2011
Identity- by-descent (IBD) sharing and results on two-point Affected Sib Pair (ASP) linkage analysis for the most interesting diabetic nephropathy susceptibility loci..
public-library-of-science.
2011
Novel Susceptibility Locus at 22q11 for Diabetic Nephropathy in Type 1 Diabetes.
public-library-of-science.
2011
Summary of the non-parametric linkage results for diabetic nephropathy on the regions showing significant or suggestive evidence of linkage..
public-library-of-science.
2011
A Single Nucleotide Polymorphism within the Acetyl-Coenzyme A Carboxylase Beta Gene Is Associated with Proteinuria in Patients with Type 2 Diabetes.
public-library-of-science.
2010
Association of the SNP in the ACACB (rs2268388) with diabetic nephropathy in several independent cohorts..
public-library-of-science.
2010
Top 4 SNPs associated with diabetic nephropathy in a genome-wide screening..
public-library-of-science.
2010
Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study.
public-library-of-science.
2008
Effect of metformin versus placebo on follow-up (intermediate and study visit) levels of HbA1c and insulin doses in 72 patients with type-1 diabetes during a one year period..
public-library-of-science.
2008
Inclusion, exclusion and withdrawal criteria.
public-library-of-science.
2008
Metabolism-related variables in 100 patients with type-1 diabetes before and after one year of treatment with metformin or placebo..
public-library-of-science.
2008
Non-hypoglycaemia-related serious adverse events in 100 patients with type-1 diabetes allocated treatment with metformin or placebo for one year..
public-library-of-science.
2008
Reported hypoglycaemic episodes in patients with type-1 diabetes during one year of treatment with metformin or placebo..
public-library-of-science.
2008
Subject characteristics at enrolment (−1 month) for 100 patients with type-1 diabetes..
public-library-of-science.
2008